An Update On Proficiency of Voltage-gated Ion Channel Blockers in the
Treatment of Inflammation-associated Diseases

Siddesh      Kelkar; Namrata      Nailwal; Nirav   Yogesh   Bhatia; Gaurav      Doshi; Sadhana      Sathaye; Angel   Pavalu   Godad
Abstract

Inflammation is the body’s mechanism to trigger the immune system, thereby preventing bacteria and viruses from manifesting their toxic effect. Inflammation plays a vital role in regulating inflammatory mediator levels to initiate the wound healing process depending on the nature of the stimuli. This process occurs due to chemical release from white blood cells by elevating blood flow to the site of action, leading to redness and increased body temperature. Currently, there are numerous Non-steroidal anti-inflammatory drugs (NSAIDs) available, but these drugs are reported with adverse effects such as gastric bleeding, progressive kidney damage, and increased risk of heart attacks when prolonged use. For such instances, alternative options need to be adopted. The introduction of voltage-gated ion channel blockers can be a substantial alternative to mask the side effects of these currently available drugs. Chronic inflammatory disorders such as rheumatoid and osteoarthritis, cancer and migraine, etc., can cause dreadful pain, which is often debilitating for the patient. The underlying mechanism for both acute and chronic inflammation involves various complex receptors, different types of cells, receptors, and proteins. The working of voltage-gated sodium and calcium channels is closely linked to both inflammatory and neuropathic pain. Certain drugs such as carbamazepine and gabapentin, which are ion channel blockers, have greater pharmacotherapeutic activity for sodium and calcium channel blockers for the treatment of chronic inflammatory pain states. This review intends to provide brief information on the mechanism of action, latest clinical trials, and applications of these blockers in treating inflammatory conditions.
Keywords: Voltage-gated ion channel blockers, inflammation, inflammatory conditions, sodium channel blockers, potassium channel blockers, calcium channel blockers.
Graphical Abstract

[1]
Soli R, Kaabi B, Barhoumi M, El-Ayeb M, Srairi-Abid N. Bioinformatic characterizations and prediction of K+ and Na+ ion channels effector toxins. BMC Pharmacol  2009; 9: 4.
 [http://dx.doi.org/10.1186/1471-2210-9-4] [PMID: 19284552]

[2]
Alexander SPH, Mathie A, Peters JA. Ion channels. Br J Pharmacol  2011; 164 (Suppl. s1): S137-74.
 [http://dx.doi.org/10.1111/j.1476-5381.2011.01649_5.x] [PMID: 21585344]

[3]
Wang L, Wang K. Highlights for the 6th International Ion Channel Conference: Ion channel structure, function, disease and therapeutics. Acta Pharm Sin B  2017; 7(6): 665-9.
 [http://dx.doi.org/10.1016/j.apsb.2017.09.007] [PMID: 29159026]

[4]
Efimova E. Cardiac conduction system. Sex Cardiac Electrophysiol  2020; 49-60.
 [http://dx.doi.org/10.1016/B978-0-12-817728-0.00005-X]

[5]
Madden JA, Rusch NJ. Electrophysiology of vascular smooth muscle. Heart Physiol Pathophysiol  2001; 213-27.

[6]
 Ion channel | biology Britannica Available from: https://www. britannica.com/science/ion-channel [Accessed on: 2022 Feb, 15].

[7]
Ananthanaryan PJC. Ananthanarayan and paniker’s textbook of microbiology PDF download. In: Medicos times Orient Longman Private Limited.   2005; pp. 71-80. Available from: https://medicostimes.com/ananthanarayan-and-panikers-microbiology-pdf/ [Accessed on: 2022 May, 23].

[8]
Bezanilla F. Voltage-gated ion channels. Biol Memb Ion Chann  2007; 81-118.
 [http://dx.doi.org/10.1007/0-387-68919-2_3]

[9]
Zhang XC, Yang H, Liu Z, Sun F. Thermodynamics of voltage-gated ion channels. Biophysics Reports  2018; 4(6): 300-19.
 [http://dx.doi.org/10.1007/s41048-018-0074-y]

[10]
Chew LA, Khanna R. CRMP2 and voltage-gated ion channels: Potential roles in neuropathic pain. Neuronal Signal  2018; 2(1): NS20170220.
 [http://dx.doi.org/10.1042/NS20170220] [PMID: 30364788]

[11]
Huang H, Pugsley MK, Fermini B, et al. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative. J Pharmacol Toxicol Methods  2017; 87: 11-23.
 [http://dx.doi.org/10.1016/j.vascn.2017.04.002] [PMID: 28408211]

[12]
Collingridge GL, Olsen RW, Peters J, Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology  2009; 56(1): 2-5.
 [http://dx.doi.org/10.1016/j.neuropharm.2008.06.063 ] [PMID: 18655795]

[13]
Absalom NL, Liao VW, Chebib M. Ligand-gated ion channels in genetic disorders and the question of efficacy. Int J Biochem Cell Biol  2020; 126: 105806.
 [http://dx.doi.org/10.1016/j.biocel.2020.105806] [PMID: 32679079]

[14]
Gielen M, Corringer PJ, Gielen M, Corringer PJ. The dual-gate model for pentameric ligand-gated ion channels activation and desensitization. J Physiol  2018; 596(10): 1873-902.
 [http://dx.doi.org/10.1113/JP275100] [PMID: 29484660]

[15]
Alexander SPH, Peters JA, Kelly E, et al. The concise guide to pharmacology 2017/18: Ligand-gated ion channels. Br J Pharmacol  2017; 174 (Suppl. 1): S130-59.
 [http://dx.doi.org/10.1111/bph.13879] [PMID: 29055038]

[16]
Eisenhut M, Wallace H. Ion channels in inflammation. Pflug Arch  2011; 461(4): 401-21.
 [http://dx.doi.org/10.1007/s00424-010-0917-y]

[17]
Hatta S, Sakamoto J, Horio Y. Ion channels and diseases. Med Electron Microsc  2002; 35(3): 117-26.
 [http://dx.doi.org/10.1007/s007950200015]

[18]
Bartoszewski R, Matalon S, Collawn JF. Ion channels of the lung and their role in disease pathogenesis. Am J Physiol Lung Cell Mol Physiol  2017; 313(5): L859-72.
 [http://dx.doi.org/10.1152/ajplung.00285.2017] [PMID: 29025712]

[19]
Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family. Genome Biol  2003; 4(3): 207.
 [http://dx.doi.org/10.1186/gb-2003-4-3-207] [PMID: 12620097]

[20]
Ren D, Navarro B, Xu H, Yue L, Shi Q, Clapham DE. A prokaryotic voltage-gated sodium channel. Science (1979)  2001; 294(5550): 2372-5.

[21]
De Lera RM, Kraus RL. Voltage-gated sodium channels: Structure, function, pharmacology, and clinical indications. J Med Chem  2015; 58(18): 7093-118.
 [http://dx.doi.org/10.1021/jm501981g] [PMID: 25927480]

[22]
Catterall WA, Zheng N. Deciphering voltage-gated Na+ and Ca+2 channels by studying prokaryotic ancestors. Trends Biochem Sci  2015; 40(9): 526-34.
 [http://dx.doi.org/10.1016/j.tibs.2015.07.002] [PMID: 26254514]

[23]
De Caen PG, Yarov YV, Scheuer T, Catterall WA. Gating charge interactions with the S1 segment during activation of a Na + channel voltage sensor. Proc Natl Acad Sci USA  2011; 108(46): 18825-30.
 [http://dx.doi.org/10.1073/pnas.1116449108] [PMID: 22042870]

[24]
DeCaen PG, Yarov-Yarovoy V, Zhao Y, Scheuer T, Catterall WA. Disulfide locking a sodium channel voltage sensor reveals ion pair formation during activation. Proc Natl Acad Sci USA  2008; 105(39): 15142-7.
 [http://dx.doi.org/10.1073/pnas.0806486105] [PMID: 18809926]

[25]
Nishino A, Okamura Y. Evolutionary history of voltage-gated sodium channels. Handb Exp Pharmacol  2017; 246: 3-32.
 [http://dx.doi.org/10.1007/164_2017_70] [PMID: 29094210]

[26]
Zakon HH. Adaptive evolution of voltage-gated sodium channels: The first 800 million years. Proc Natl Acad Sci USA  2012; 109 (Suppl. 1): 10619-25.
 [http://dx.doi.org/10.1073/pnas.1201884109] [PMID: 22723361]

[27]
Payandeh J, Scheuer T, Zheng N, Catterall WA. The crystal structure of a voltage-gated sodium channel. Nature  2011; 475(7356): 353-8.
 [http://dx.doi.org/10.1038/nature10238]

[28]
Zhang X, Ren W, Decaen P, et al. Crystal structure of an orthologue of the NaChBac voltage-gated sodium channel. Nature  2012; 486(7401): 130-4.
 [http://dx.doi.org/10.1038/nature11054]

[29]
Savio GE, Gollob MH, Darbar D. Voltage-gated sodium channels: Biophysics, pharmacology, and related channelopathies. Front Pharmacol  2012; 3: 124.
 [http://dx.doi.org/10.3389/fphar.2012.00124] [PMID: 22798951]

[30]
Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci  2006; 9(9): 1142-9.
 [http://dx.doi.org/10.1038/nn1754]

[31]
Sokolov S, Scheuer T, Catterall WA. Gating pore current in an inherited ion channelopathy. Nature  2007; 446(7131): 76-8.
 [http://dx.doi.org/10.1038/nature05598] [PMID: 17330043]

[32]
Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm  2010; 7(1): 33-46.
 [http://dx.doi.org/10.1016/j.hrthm.2009.09.069] [PMID: 20129283]

[33]
Dib HSD, Black JA, Waxman SG. Voltage-gated sodium channels: Therapeutic targets for pain. Pain Med  2009; 10(7): 1260-9.
 [http://dx.doi.org/10.1111/j.1526-4637.2009.00719.x ] [PMID: 19818036]

[34]
Amaya F, Wang H, Costigan M, et al. The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci  2006; 26(50): 12852-60.
 [http://dx.doi.org/10.1523/JNEUROSCI.4015-06.2006 ] [PMID: 17167076]

[35]
Ekberg J, Adams DJ. Neuronal voltage-gated sodium channel subtypes: Key roles in inflammatory and neuropathic pain. Int J Biochem Cell Biol  2006; 38(12): 2005-10.
 [http://dx.doi.org/10.1016/j.biocel.2006.06.008] [PMID: 16919992]

[36]
Ritter AM, Martin WJ, Thorneloe KS. The voltage-gated sodium channel Nav1.9 is required for inflammation-based urinary bladder dysfunction. Neurosci Lett  2009; 452(1): 28-32.
 [http://dx.doi.org/10.1016/j.neulet.2008.12.051] [PMID: 19146922]

[37]
Momin A, Wood JN. Sensory neuron voltage-gated sodium channels as analgesic drug targets. Curr Opin Neurobiol  2008; 18(4): 383-8.
 [http://dx.doi.org/10.1016/j.conb.2008.08.017] [PMID: 18824099]

[38]
Priest BT. Future potential and status of selective sodium channel blockers for the treatment of pain. Curr Opin Drug Discov Devel  2009; 12(5): 682-92.
 [PMID: 19736626]

[39]
Theile JW, Cummins TR. Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front Pharmacol  2011; 2: 54.
 [http://dx.doi.org/10.3389/fphar.2011.00054] [PMID: 22007172]

[40]
Bhattacharya A, Wickenden AD, Chaplan SR. Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeutics  2009; 6(4): 663-78.
 [http://dx.doi.org/10.1016/j.nurt.2009.08.001]

[41]
Matulenko M, Scanio M, Kort M. Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem  2009; 9(4): 362-76.
 [http://dx.doi.org/10.2174/156802609788317883] [PMID: 19442207]

[42]
Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol  2011; 3(8): a003947.
 [http://dx.doi.org/10.1101/cshperspect.a003947] [PMID: 21746798]

[43]
Shilpi JA, Uddin SJ. Analgesic and antipyretic natural products. Annu Rep Med Chem  2020; 55: 435-58.
 [http://dx.doi.org/10.1016/bs.armc.2020.03.003]

[44]
Simms BA, Zamponi GW. Neuronal voltage-gated calcium channels: Structure, function, and dysfunction. Neuron  2014; 82(1): 24-45.
 [http://dx.doi.org/10.1016/j.neuron.2014.03.016] [PMID: 24698266]

[45]
Hogan PG, Rao A. Store-operated calcium entry: Mechanisms and modulation. Biochem Biophys Res Commun  2015; 460(1): 40-9.
 [http://dx.doi.org/10.1016/j.bbrc.2015.02.110] [PMID: 25998732]

[46]
Ben JM, Yue DT. Calmodulin regulation (calmodulation) of voltage-gated calcium channels. J Gen Physiol  2014; 143(6): 679-92.
 [http://dx.doi.org/10.1085/jgp.201311153] [PMID: 24863929]

[47]
Verret F, Wheeler G, Taylor AR, Farnham G, Brownlee C. Calcium channels in photosynthetic eukaryotes: Implications for evolution of calcium‐based signalling. New Phytol  2010; 187(1): 23-43.
 [http://dx.doi.org/10.1111/j.1469-8137.2010.03271.x ] [PMID: 20456068]

[48]
Senatore A, Raiss H, Le P. Physiology and evolution of voltage-gated calcium channels in early diverging animal phyla: Cnidaria, placozoa, porifera and ctenophora. Front Physiol  2016; 7: 481.
 [http://dx.doi.org/10.3389/fphys.2016.00481] [PMID: 27867359]

[49]
Dolphin AC. A short history of voltage-gated calcium channels. Br J Pharmacol  2006; 147(S1): S56-62.
 [http://dx.doi.org/10.1038/sj.bjp.0706442] [PMID: 16402121]

[50]
Catterall WA, Perez RE, Snutch TP, Striessnig J. International union of pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev  2005; 57(4): 411-25.
 [http://dx.doi.org/10.1124/pr.57.4.5] [PMID: 16382099]

[51]
Dolphin AC. Voltage-gated calcium channels and their auxiliary subunits: Physiology and pathophysiology and pharmacology. J Physiol  2016; 594(19): 5369-90.
 [http://dx.doi.org/10.1113/JP272262] [PMID: 27273705]

[52]
Davies A, Kadurin I, Alvarez-Laviada A, et al. The α 2 δ subunits of voltage-gated calcium channels form GPI-anchored proteins, a posttranslational modification essential for function. Proc Natl Acad Sci USA  2010; 107(4): 1654-9.
 [http://dx.doi.org/10.1073/pnas.0908735107] [PMID: 20080692]

[53]
Edvardson S, Oz S, Abulhijaa FA, et al. Early infantile epileptic encephalopathy associated with a high voltage gated calcium channelopathy. J Med Genet  2013; 50(2): 118-23.
 [http://dx.doi.org/10.1136/jmedgenet-2012-101223 ] [PMID: 23339110]

[54]
Bidaud I, Mezghrani A, Swayne LA, Monteil A, Lory P. Voltage-gated calcium channels in genetic diseases. Biochimica et Biophysica Acta (BBA) -. Mol Cell Res  2006; 1763(11): 1169-74.

[55]
Pietrobon D. Calcium channels and channelopathies of the central nervous system. Mol Neurobiol  2002; 25(1): 31-50.
 [http://dx.doi.org/10.1385/MN:25:1:031]

[56]
McGivern JG. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov Today  2006; 11(5-6): 245-53.
 [http://dx.doi.org/10.1016/S1359-6446(05)03662-7 ] [PMID: 16580601]

[57]
Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Brain Res Rev  2009; 60(1): 84-9.
 [http://dx.doi.org/10.1016/j.brainresrev.2008.12.021 ] [PMID: 19162069]

[58]
Doan L. Voltage-gated calcium channels and pain. Tech Reg Anesth Pain Manage  2010; 14(2): 42-7.
 [http://dx.doi.org/10.1053/j.trap.2010.03.003]

[59]
Vink S, Alewood PF. Targeting voltage-gated calcium channels: Developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain. Br J Pharmacol  2012; 167(5): 970-89.
 [http://dx.doi.org/10.1111/j.1476-5381.2012.02082.x ] [PMID: 22725651]

[60]
Eisenberg MJ, Brox A, Bestawros AN. Calcium channel blockers: An update. Am J Med  2004; 116(1): 35-43.
 [http://dx.doi.org/10.1016/j.amjmed.2003.08.027] [PMID: 14706664]

[61]
Nimmrich V, Eckert A. Calcium channel blockers and dementia. Br J Pharmacol  2013; 169(6): 1203-10.
 [http://dx.doi.org/10.1111/bph.12240] [PMID: 23638877]

[62]
Taddei S, Bruno RM. Calcium channel blockers. Encyclopedia of Endocrine Diseases  2018; 689-95.

[63]
Flenady V, Wojcieszek AM, Papatsonis DNM, et al. Calcium channel blockers for inhibiting preterm labour and birth. Cochrane Database of Syst Rev  2014; 2014(6)
 [http://dx.doi.org/10.1002/14651858.CD002255.pub2]

[64]
Aria MM. Bioelectricity and excitable membranes. Electrophysiol Measurements Study Neural Interfaces  2020; 1-23.
 [http://dx.doi.org/10.1016/B978-0-12-817070-0.00001-4]

[65]
Yellen G. The voltage-gated potassium channels and their relatives. Nature  2002; 419(6902): 35-42.
 [http://dx.doi.org/10.1038/nature00978]

[66]
Voltage-Gated K+ channels.  Available from: https://www.ks.uiuc. edu/Research/kvchannel/ [Accessed on: 2022 Feb, 11].

[67]
Morais-Cabral JH, Zhou Y, MacKinnon R. Energetic optimization of ion conduction rate by the K+ selectivity filter. Nature  2001; 414(6859): 37-42.

[68]
Zhou Y, Morais CJH, Kaufman A, Mackinnon R. Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 Å resolution. Nature  2001; 414(6859): 43-8.

[69]
Moran Y, Barzilai MG, Liebeskind BJ, Zakon HH. Evolution of voltage-gated ion channels at the emergence of Metazoa. J Exp Biol  2015; 218(4): 515-25.
 [http://dx.doi.org/10.1242/jeb.110270] [PMID: 25696815]

[70]
Cordero MJF, Jogini V, Lewis A, et al. Molecular driving forces determining potassium channel slow inactivation. Nat Struct Mol Biol  2007; 14(11): 1062-9.
 [http://dx.doi.org/10.1038/nsmb1309]

[71]
Bean BP. The action potential in mammalian central neurons. Nature Rev Neurosci  2007; 8(6): 451-65.
 [http://dx.doi.org/10.1038/nrn2148]

[72]
Catterall WA. Ion channel protein superfamily. Encycl Biol Chem  2013; 648-52.
 [http://dx.doi.org/10.1016/B978-0-12-378630-2.00133-X]

[73]
Herguedas B, Krieger J, Greger IH. Receptor heteromeric assembly-how it works and why it matters: The case of ionotropic glutamate receptors. Prog Mol Biol Transl Sci  2013; 117: 361-86.
 [http://dx.doi.org/10.1016/B978-0-12-386931-9.00013-1 ] [PMID: 23663975]

[74]
Smith M. Epilepsy and movement disorders. Mecha Genet Neurodevel Cognitive Disord  2021; 195-224.
 [http://dx.doi.org/10.1016/B978-0-12-821913-3.00009-3]

[75]
Maddison P, Mills KR, Newsom DJ. Clinical electrophysiological characterization of the acquired neuromyotonia phenotype of autoimmune peripheral nerve hyperexcitability. Muscle Nerve  2006; 33(6): 801-8.
 [http://dx.doi.org/10.1002/mus.20536] [PMID: 16570308]

[76]
Irani SR, Vincent A. Voltage-gated potassium channel-complex autoimmunity and associated clinical syndromes. Handb Clin Neurol  2016; 133: 185-97.
 [http://dx.doi.org/10.1016/B978-0-444-63432-0.00011-6 ] [PMID: 27112678]

[77]
Olsen ML, Schade S, Lyons SA, Amaral MD, Sontheimer H. Expression of voltage-gated chloride channels in human glioma cells. J Neurosci  2003; 23(13): 5572-82.
 [http://dx.doi.org/10.1523/JNEUROSCI.23-13-05572.2003] [PMID: 12843258]

[78]
Wondergem R, Gong W, Monen SH, et al. Blocking swelling‐activated chloride current inhibits mouse liver cell proliferation. J Physiol  2001; 532(3): 661-72.
 [http://dx.doi.org/10.1111/j.1469-7793.2001.0661e.x ] [PMID: 11313437]

[79]
Tilly BC, Mancini GMS, Bijman J, et al. Nucleotide-activated chloride channels in lysosomal membranes. Biochem Biophys Res Commun  1992; 187(1): 254-60.
 [http://dx.doi.org/10.1016/S0006-291X(05)81485-8 ] [PMID: 1325789]

[80]
Matthews G, Neher E, Penner R, Matthews G, Neher E, Penner R. Second messenger-activated calcium influx in rat peritoneal mast cells. J Physiol  1989; 418(1): 105-30.
 [http://dx.doi.org/10.1113/jphysiol.1989.sp017830] [PMID: 2559968]

[81]
Borsani G, Rugarli EI, Taglialatela M, Wong C, Ballabio A. Characterization of a human and murine gene (CLCN3) sharing similarities to voltage-gated chloride channels and to a yeast integral membrane protein. Genomics  1995; 27(1): 131-41.
 [http://dx.doi.org/10.1006/geno.1995.1015] [PMID: 7665160]

[82]
Ranganathan R, Lewis JH, MacKinnon R. Spatial localization of the K+ channel selectivity filter by mutant cycle-based structure analysis. Neuron  1996; 16(1): 131-9.
 [http://dx.doi.org/10.1016/S0896-6273(00)80030-6 ] [PMID: 8562077]

[83]
Lü Q, Miller C. Silver as a probe of pore-forming residues in a potassium channel. Science  1995; 268(5208): 304-7.

[84]
George AL Jr, Crackower MA, Abdalla JA, Hudson AJ, Ebers GC. Molecular basis of Thomsen’s disease (autosomal dominant myotonia congenita). Nat Genet  1993; 3(4): 305-10.
 [http://dx.doi.org/10.1038/ng0493-305] [PMID: 7981750]

[85]
Fahlke C, Beck CL, George AL Jr. A mutation in autosomal dominant myotonia congenita affects pore properties of the muscle chloride channel. Proc Natl Acad Sci USA  1997; 94(6): 2729-34.
 [http://dx.doi.org/10.1073/pnas.94.6.2729] [PMID: 9122265]

[86]
Jentsch TJ, Steinmeyer K, Schwarz G. Primary structure of Torpedo marmorata chloride channel isolated by expression cloning in Xenopus oocytes. Nature  1990; 348(6301): 510-4.
 [http://dx.doi.org/10.1038/348510a0]

[87]
Gründer S, Thiemann A, Pusch M, Jentsch TJ. Regions involved in the opening of CIC-2 chloride channel by voltage and cell volume. Nature  1992; 360(6406): 759-62.

[88]
Kieferle S, Fong P, Bens M, Vandewalle A, Jentsch TJ. Two highly homologous members of the ClC chloride channel family in both rat and human kidney. Proc Natl Acad Sci USA  1994; 91(15): 6943-7.
 [http://dx.doi.org/10.1073/pnas.91.15.6943] [PMID: 8041726]

[89]
Middleton RE, Pheasant DJ, Miller C. Purification, reconstitution, and subunit composition of a voltage-gated chloride channel from Torpedo electroplax. Biochemistry  1994; 33(45): 13189-98.
 [http://dx.doi.org/10.1021/bi00249a005] [PMID: 7947726]

[90]
Jentsch TJ, Günther W, Pusch M, Schwappach B. Properties of voltage-gated chloride channels of the ClC gene family. J Physiol  1995; 482 (Suppl.): 19-25.
 [http://dx.doi.org/10.1113/jphysiol.1995.sp020560] [PMID: 7730971]

[91]
Jurenka JS. Jurenka. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Altern Med Rev  2009; 14(2): 141-53.

[92]
Aggarwal B, Chandra Bharti A. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res  2003; 23(1A): 363-98.

[93]
Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res  1991; 51(3): 813-9.

[94]
Cho J-W, Lee K-S, Kim C-W. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med  2007; 19(3): 469-74.

[95]
Liu JY, Lin SJ, Lin JK. Inhibitory effects of curcumin on protein kinase C activity induced by 12- O -tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis  1993; 14(5): 857-61.
 [http://dx.doi.org/10.1093/carcin/14.5.857] [PMID: 8504477]

[96]
Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol  2011; 25(6): 447-52.
 [http://dx.doi.org/10.1111/j.2042-7158.1973.tb09131.x ] [PMID: 4146582]

[97]
Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain  2012; 153(6): 1148-58.
 [http://dx.doi.org/10.1016/j.pain.2012.03.003] [PMID: 22494920]

[98]
Tuttle AH, Tohyama S, Ramsay T, et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain  2015; 156(12): 2616-26.
 [http://dx.doi.org/10.1097/j.pain.0000000000000333 ] [PMID: 26307858]

[99]
Rice ASC, Dworkin RH, McCarthy TD, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet  2014; 383(9929): 1637-47.
 [http://dx.doi.org/10.1016/S0140-6736(13)62337-5 ] [PMID: 24507377]

[100]
Dworkin RH, Turk DC, Peirce-Sandner S, et al. Assay sensitivity and study features in neuropathic pain trials: An ACTTION meta-analysis. Neurology  2013; 81(1): 67-75.
 [http://dx.doi.org/10.1212/WNL.0b013e318297ee69 ] [PMID: 23700332]

[101]
Truini A, Garcia-Larrea L, Cruccu G. Reappraising neuropathic pain in humans-how symptoms help disclose mechanisms. Nature Reviews Neurology  2013; 9(10): 572-82.

[102]
Demant DT, Lund K, Finnerup NB, et al. Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype. Pain  2015; 156(11): 2234-44.
 [http://dx.doi.org/10.1097/j.pain.0000000000000266 ] [PMID: 26090758]

[103]
Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol  1986; 24(12): 651-4.
 [PMID: 3546166]

[104]
Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferu-loyl methane). Indian J Med Res  1980; 1: 632-4. PubMed Available from: https://pubmed.ncbi. nlm.nih.gov/7390600/ [Accessed on: 2022 Feb, 11].
 [PMID: 7390600]

[105]
Blockade of vascular potassium channels during human endotoxemia - Full text view.  Available from: https://clinicaltrials.gov/ct2/show/study/NCT00185003?term=ion+channels&cond=Inflammation&draw=2&rank=3 [Accessed on: 2022 Feb, 11].

[106]
Colchicine counteracting inflammation in covid-19 pneumonia - tabular view. ClinicalTrialsgov  Available from: https://clinicaltrials.gov/ct2/show/record/NCT04322565?term=ion+channels&cond=Inflammation&draw=2&rank=1 [Accessed on: 2022 Feb, 11].

[107]
Amiloride hydrochlorothiazide as treatment of acute inflammation of the optic nerve - full text view. ClinicalTrialsgov  Available from: https://clinicaltrials.gov/ct2/show/NCT01879527?term=ion+channels&cond=Inflammation&draw=2&rank=2 [Accessed on: 2022 Feb, 11].

[108]
Impact of lidocaine administration on postoperative complications during lung resection surgery - Full text view. ClinicalTrialsgov  Available from: https://clinicaltrials.gov/ct2/show/NCT03905837? term=sodium+channels&cond=Inflammation&draw=2&rank=4 [Accessed on: 2022 Feb, 11].

[109]
Lidocaine-ketamine versus ketamine for induction of anesthesia in septic shock patients-full text view. ClinicalTrialsgov  Available from: https://clinicaltrials.gov/ct2/show/NCT03844984?term=sodium+channels&cond=Inflammation&draw=2&rank=10 [Accessed on: 2022 Feb, 11].

[110]
Predictive factors affecting the efficacy of local tetracycline injection for treatment of post-mastectomy seroma. - tabular view. ClinicalTrialsgov  Available from: https://clinicaltrials.gov/ct2/show/record/NCT04730674?term=sodium+channels&cond=Inflammation&draw=2&rank=7 [Accessed on: 2022 Feb, 11].

[111]
Comparison of fimasartan versus amlodipine therapy on carotid plaque inflammation - full text view. ClinicalTrialsgov  Available from: https://clinicaltrials.gov/ct2/show/NCT02378064?term=calcium+channels&cond=Inflammation&draw=2&rank=1 [Accessed on: 2022 Feb, 11].

[112]
A pilot study of use of calcium channel blocker to decrease inflammation and pain in hereditary pancreatitis - full text view. ClinicalTrialsgov  Available from: https://clinicaltrials.gov/ct2/show/NCT00156403?term=calcium+channels&cond=Inflammation&draw=2&rank=2 [Accessed on: 2022 Feb, 11].

[113]
Drug-disease interaction in crohn’s disease - tabular view. ClinicalTrialsgov  Available from: https://clinicaltrials.gov/ct2/show/record/NCT01261286?term=calcium+channels&cond=Inflammation&draw=2&rank=4 [Accessed on: 2022 Feb, 11].
Cite As
Current Drug Targets

An Update On Proficiency of Voltage-gated Ion Channel Blockers in the Treatment of Inflammation-associated Diseases

Abstract

Graphical Abstract
